Pascale Foundation, Member of Italy s Institute of Hospitalization and Treatment, Joins Caris Life Sciences Precision Oncology Alliance
News provided by
Share this article
Share this article
IRVING, Texas, April 6, 2021 /PRNewswire/ Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Istituto Nazionale Tumori IRCCS Fondazione G. Pascale (Pascale Foundation) has joined Caris Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer.
IRVING, Texas, April 6, 2021
– Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that the Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale” (Pascale Foundation) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve the clinical outcomes of patients with cancer. Pascale Foundation is the largest clinical care and research cancer center in Southern Italy. The institute pursues clinical research and applied research in the biomedical field, along with the organization and management of health services. Pascale Foundation focuses on patient-centered care through research and innovation in dail
Patients with cancer demonstrate particularly poor outcomes from COVID-19
. Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, has published results from a study that analyzed a cohort of 38,628 cancer patients to gain insight into why cancer patients have poor outcomes from COVID-19. Investigators identified that ACE2, TMPRSS2, and other proteases that are key factors necessary for viral attachment to and entry into target cells.
Caris study results have been published in
Scientific Reports, A Nature Research Journal, finding substantial variability of expression of ACE2 and TMPRSS2 across tumor types while identifying subpopulations expressing ACE2 at very high levels. This study provides the first systematic assessment of RNA expression of key molecules involved in the infectious process, and offers a biological explanation for why cancer patients do poorly when afflicted wi
Caris Precision Oncology Alliance Continues to Grow Internationally as it Welcomes Curie Oncology from Singapore
Curie Oncology expands Caris collaborative network of oncology institutions focused on research into personalized therapies through precision medicine
News provided by
Share this article
IRVING, Texas, March 9, 2021 /PRNewswire/
Caris Life Sciences®, a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine, announced today that Curie Oncology from Singapore has joined Caris Precision Oncology Alliance™ (POA). The POA is a collaborative network of leading cancer centers that work together to advance comprehensive cancer profiling and establish standards of care for molecular testing in oncology through research focused on predictive and prognostic markers that improve clinical outcomes of cancer patients.